rs1042711
This is a regulatory region variant variant in the ADRB2 gene.
▶GWAS Catalog Trait Associations (1)
Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.
GWAS Catalog Trait Associations (1)
Genome-wide significant associations (p < 5×10⁻⁸) from the NHGRI-EBI GWAS Catalog.
eosinophil count
▶ClinVar annotation
Beta-2-adrenoreceptor agonist, reduced response to
View on ClinVar →▶Research that mentions this SNP (3)
▶The correlation between SNPs within the gene of adrenergic receptor and neuropeptide Y and risk of cervical vertigoAssociationN=420Jianlong Han et al.(2018)· Journal of Clinical Laboratory Analysis
Case-control study of 216 cervical vertigo patients and 204 controls identifying SNPs in ADRA1A, ADRB1, ADRB2, and NPY genes significantly associated with cervical vertigo risk (ORs 0.62-2.07) and clinical prognosis markers (JOA score and recovery rate). ADRA1A rs3802241 showed OR=2.07 for disease risk and protective effect on prognosis; NPY variants predicted recovery outcomes.
▶Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis BReviewMauro Viganò et al.(2013)· Hepatology
This comprehensive review examines the genetic background of nonalcoholic fatty liver disease (NAFLD), focusing on variants identified by genome-wide association studies (GWAS) and candidate gene studies. The most significant GWAS-identified variants are PNPLA3 rs738409 (I148M), which strongly associates with increased liver steatosis, fibrosis severity, and HCC risk (12-fold increased risk for homozygous carriers), and TM6SF2 rs58542926 (E167K), which increases NASH progression but reduces cardiovascular risk. The review also discusses numerous candidate genes involved in lipid and glucose metabolism and liver injury mechanisms.
▶Dissociation betweenAPOC3variants, hepatic triglyceride content and insulin resistanceReviewJulia Kozlitina et al.(2011)· Hepatology
Comprehensive review of genetic background in nonalcoholic fatty liver disease (NAFLD). The PNPLA3 I148M variant (rs738409 C>G) is identified as a major genetic player strongly associated with increased liver fat content, NASH development, fibrosis severity, and HCC risk. The TM6SF2 E167K variant (rs58542926) emerges as another key contributor to NAFLD pathogenesis and disease progression. Multiple additional GWAS-identified variants and candidate genes are reviewed for their roles in NAFLD susceptibility and progression.
About ADRB2
This gene encodes beta-2-adrenergic receptor which is a member of the G protein-coupled receptor superfamily. This receptor is directly associated with one of its ultimate effectors, the class C L-type calcium channel Ca(V)1.2. This receptor-channel complex also contains a G protein, an adenylyl cyclase, cAMP-dependent kinase, and the counterbalancing phosphatase, PP2A. The assembly of the signaling complex provides a mechanism that ensures specific and rapid signaling by this G protein-coupled receptor. This receptor is also a transcription regulator of the alpha-synuclein gene, and together, both genes are believed to be associated with risk of Parkinson's Disease. This gene is intronless. Different polymorphic forms, point mutations, and/or downregulation of this gene are associated with nocturnal asthma, obesity, type 2 diabetes and cardiovascular disease. [provided by RefSeq, Oct 2019]
View all ADRB2 variants →Gene information from NCBI Gene. Variant classifications from ClinVar.
Community Wiki
No community notes yet for this variant. Sign in to start one.
Comments
Sign in to join the discussion.
Loading comments…